Related Experiment Video

Updated: Jul 14, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

Effects of antidepressant treatment following myocardial infarction

Joost P van Melle1, Peter de Jonge, Adriaan Honig

  • 1Department of Cardiology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB, The Netherlands.

The British Journal of Psychiatry : the Journal of Mental Science
|June 2, 2007
PubMed

Insights

Antidepressant treatment for patients with myocardial infarction did not improve long-term depression or cardiac outcomes. This study found no significant differences in depression status or cardiac events between treated and usual care groups.

Area of Science:

  • Cardiology
  • Psychiatry
  • Clinical Trials

Background:

  • Depression after myocardial infarction (MI) is linked to worse cardiac prognosis.
  • The efficacy of antidepressant treatment for long-term depression and cardiac outcomes post-MI remains uncertain.

Purpose of the Study:

  • To assess the effectiveness of antidepressant treatment versus usual care in patients following myocardial infarction.
  • To evaluate the impact on long-term depression status and cardiac event rates.

Main Methods:

  • A multicenter randomized controlled trial involving 2177 myocardial infarction patients.
  • Patients were assessed for ICD-10 depression and randomized to antidepressant intervention or usual care.
  • Outcomes, including depression status and cardiac events, were evaluated at 18 months post-MI.

Main Results:

  • No significant differences in Beck Depression Inventory scores or ICD-10 depression prevalence between groups.
  • The cardiac event rate was similar in both the intervention (14%) and usual care (13%) groups.
  • Antidepressant treatment did not demonstrate a statistically significant effect on cardiac events (OR=1.07, 95% CI 0.57-2.00).

Conclusions:

  • Antidepressant treatment offers no significant benefit for long-term depression status in patients post-myocardial infarction.
  • The study concludes that antidepressant therapy does not improve cardiac prognosis in this patient population.
Abstract

More Related Videos

Caspase-3 Activity in the Rat Amygdala Measured by Spectrofluorometry After Myocardial Infarction08:41

Caspase-3 Activity in the Rat Amygdala Measured by Spectrofluorometry After Myocardial Infarction

Published on: January 12, 2016

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...